TickerGuard
Buy Day today: Neutral (59) Mixed market breadth · major macro event coming up
TAK

Takeda Pharmaceutical Co Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

17.40$ -0.1% vs. previous close Closing price · As of: Aug 13, 2026

Statements

Income Statement

Takeda Pharmaceutical Co Ltd (TAK) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2026), "Revenue" came in at 4,777,450 million JPY. Tick rows to compare them in a chart.

All figures in millions of JPY.

Tick rows to compare them in a chart (up to 4)

Income Statement TAK
Line item 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
1,777,824 1,807,378 1,732,051 1,770,531 2,097,224 3,291,188 3,197,812 3,569,006 4,027,478 4,263,762 4,581,551 4,777,450
520,990 535,405 558,755 495,921 659,690 1,089,764 994,308 1,106,846 1,244,072 1,431,505 1,580,217 2,338,119
1,256,834 1,271,973 1,173,296 1,274,610 1,437,534 2,201,424 2,203,504 2,462,160 2,783,406 2,832,257 3,001,334 2,439,332
382,096 345,927 312,303 325,441 368,298 492,381 455,833 526,087 633,325 729,924 730,227 716,688
499,401 650,773 619,061 628,106 717,599 964,737 875,663 886,361 997,309 1,053,819 1,104,766 1,084,215
1,386,088 1,141,145 1,017,429 1,032,821 1,277,169 2,101,016 1,694,235 2,001,315 2,292,900 2,618,182 2,658,748 1,866,289
-129,254 130,828 155,867 241,789 204,969 100,408 509,269 460,844 490,505 214,075 342,586 573,042
32,878 31,931 23,250 31,928 48,158 1,459 130,806 122,432 116,973 1,062 137,311 379,136
-145,437 120,539 143,346 217,205 94,896 -60,754 366,235 302,571 375,090 52,791 175,084 275,880
-2,403 37,059 27,833 30,497 -14,118 -105,044 -9,936 72,405 58,052 -91,406 66,941 72,274
-145,775 80,166 114,940 186,886 109,126 44,241 376,005 230,059 317,017 144,067 107,928 203,327
57,287 349,851 296,876 359,956 464,216 671,905 983,718 1,183,213 1,284,067 1,143,936 1,210,512 1,419,633

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?